[{"name":"For the Motion \u2013 Closing Remarks (ID 918)","mode":"","is_cme":false,"info":{"presentation":"For the Motion – Closing Remarks <small>(ID 918)<\/small>","session":"Eisai - Industry Satellite Symposium: In the modern management of HER2-\/HR+ MBC, should chemotherapy be the treatment of last resort? <small>(ID 49)<\/small>","presenter":"Peter Schmid<small> (London, United Kingdom)<\/small>","photo":null},"playlist":[{"name":"For the Motion \u2013 Closing Remarks","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/breast2020\/49\/v\/918_2p.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/breast2020\/49\/v\/918_2p.mp4","cover":"","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/breast2020\/49\/v\/918_2p.vtt","thumbnails":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/breast2020\/49\/v\/918_2p-thumbnails.vtt"}]}]{"provider":"CTI","provider_live":0,"type":1,"code":"9L240gQ02Vk"}